R-BAC regimen in the treatment of relapsed and refractory diffuse large B-cell lymphoma

R-BAC regimen for the treatment of relapsed and refractory diffuse large B-cell lymphoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033337

Enrollment

Unknown

Registered

2020-05-28

Start date

2020-07-01

Completion date

Unknown

Last updated

2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed and refractory diffuse large B-cell lymphoma

Interventions

experimental group:Rituximab, Bendamustine combined with Cytarabine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with diffuse large B-cell lymphoma (DLBCL) in accordance with who's lymphoma classification revised in 2016 and NCCN guidelines in 2019; 2. Patients who have received the first-line treatment plan (R-CHOP) of DLBCL and have not fully relieved or relapsed within one year; or patients who have used multiple plans but not fully relieved; 3. Patients aged 18-80 years; 4. Patients with physical fitness score <= 2; 5. Patients must provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with obvious abnormal function of heart, liver, kidney and other important organs or other tumors; 2. Patients with autoimmune diseases; 3. Patients with mental illness; 4. Pregnant or nursing patients; 5. Patients who are participating in other intervention studies.

Design outcomes

Primary

Measure	Time frame
ORR;	—

Secondary

Measure	Time frame
Agranulocytosis time;Thrombocytopenia time;Incidence of infection;medication side effect;	—

Countries

China

Contacts

Public ContactPeng Hongling

Xiangya Second Hospital of Central South University

penghongling@aliyun.com+86 13975806137

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026